Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Yagyu

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Biomaterials|January 31, 2016
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirusFrancesca Del Bufalo, Teresa Manzo, Valentina Hoyos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2015
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung CancersValentina Hoyos, Francesca Del Bufalo, Shigeki Yagyu, et al.
Molecular Therapy Oncolytics|October 20, 2023
Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancersThanyavi Chinsuwan, Koichi Hirabayashi, Shuji Mishima, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 24, 2026
A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapyRyo Ikushima, Hideki Yoshida, Satoru Oya, et al.
BMC Pediatrics|May 14, 2020
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocolTomoko Iehara, Akihiro Yoneda, Atsushi Kikuta, et al.
Molecular Therapy Oncolytics|October 12, 2023
Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancersThanyavi Chinsuwan, Koichi Hirabayashi, Shuji Mishima, et al.
Biochemical and Biophysical Research Communications|October 16, 2012
All-trans retinoic acid combined with 5-Aza-2'-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cellsAtsushi Fujiki, Toshihiko Imamura, Kenichi Sakamoto, et al.
Cancer Science|March 3, 2025
Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell CarcinomaYusuke Ito, Toshihiro Suzuki, Manami Shimomura, et al.
Biochemical and Biophysical Research Communications|November 21, 2007
Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcomaKen Kikuchi, Kunihiko Tsuchiya, Osamu Otabe, et al.
Blood|May 6, 2015
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugsSoranobu Ninomiya, Neeharika Narala, Leslie Huye, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Biomaterials|January 31, 2016
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirusFrancesca Del Bufalo, Teresa Manzo, Valentina Hoyos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2015
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung CancersValentina Hoyos, Francesca Del Bufalo, Shigeki Yagyu, et al.
Molecular Therapy Oncolytics|October 20, 2023
Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancersThanyavi Chinsuwan, Koichi Hirabayashi, Shuji Mishima, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 24, 2026
A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapyRyo Ikushima, Hideki Yoshida, Satoru Oya, et al.
BMC Pediatrics|May 14, 2020
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocolTomoko Iehara, Akihiro Yoneda, Atsushi Kikuta, et al.
Molecular Therapy Oncolytics|October 12, 2023
Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancersThanyavi Chinsuwan, Koichi Hirabayashi, Shuji Mishima, et al.
Biochemical and Biophysical Research Communications|October 16, 2012
All-trans retinoic acid combined with 5-Aza-2'-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cellsAtsushi Fujiki, Toshihiko Imamura, Kenichi Sakamoto, et al.
Cancer Science|March 3, 2025
Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell CarcinomaYusuke Ito, Toshihiro Suzuki, Manami Shimomura, et al.
Biochemical and Biophysical Research Communications|November 21, 2007
Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcomaKen Kikuchi, Kunihiko Tsuchiya, Osamu Otabe, et al.
Blood|May 6, 2015
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugsSoranobu Ninomiya, Neeharika Narala, Leslie Huye, et al.
Pageof 7